Product Description
Brenipatide (GIP/GLP-1 Coagonist III) is a biologic entity being studied for the treatment of cardiometabolic-related diseases. (Sourced from: https://www.lilly.com/science/research-development/pipeline)
Mechanisms of Action: GIP Agonist, GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Japan, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Singapore, Slovakia, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 36
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Alcoholism|Depressive Disorder, Major
Phase 2: Asthma|Bipolar Disorder|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Constipation|Diarrhea|Emphysema|Irritable Bowel Syndrome|Opioid-Related Disorders|Schizophrenia|Tobacco Use Disorder
Phase 1: Healthy Volunteers|Hepatic Insufficiency|Kidney Failure, Chronic|Obesity|Overweight
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07759245 |
RENEW-COPD | P2 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease|Bronchitis, Chronic|Emphysema |
2028-05-01 |
79% |
2026-08-13 |
Primary Endpoints|Treatments |
NCT07219173 |
J2S-MC-GZMR | P2 |
Recruiting |
Asthma |
2028-04-01 |
73% |
2025-10-28 |
|
NCT07420283 |
RENEW-Op-1 | P2 |
Recruiting |
Opioid-Related Disorders |
2028-03-01 |
79% |
2026-04-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT07219953 |
RENEW-ALC-2 | P3 |
Recruiting |
Alcoholism |
2028-04-01 |
53% |
2025-11-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07412756 |
RENEW-MDD-1 | P3 |
Recruiting |
Depressive Disorder, Major |
2028-02-01 |
66% |
2026-03-24 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07286175 |
RENEW-Bipolar-1 | P2 |
Recruiting |
Bipolar Disorder |
2027-11-01 |
76% |
2025-12-17 |
Primary Endpoints|Treatments |
NCT07410507 |
RENEW-Scz-1 | P2 |
Recruiting |
Schizophrenia |
2027-11-01 |
77% |
2026-03-26 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07545759 |
RENEW-IBS-D | P2 |
Recruiting |
Irritable Bowel Syndrome|Diarrhea |
2027-09-01 |
81% |
2026-05-14 |
|
NCT07545772 |
RENEW-IBS-C | P2 |
Recruiting |
Irritable Bowel Syndrome|Constipation |
2027-07-01 |
79% |
2026-07-08 |
|
NCT07223840 |
RENEW-Smk-1 | P2 |
Recruiting |
Tobacco Use Disorder |
2027-02-01 |
71% |
2025-11-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06606106 |
J2S-MC-GZMD | P1 |
Active, not recruiting |
Overweight|Obesity |
2026-07-01 |
88% |
2026-01-21 |
|
NCT07165002 |
J2S-MC-GZML | P1 |
Recruiting |
Hepatic Insufficiency |
2026-08-01 |
2025-11-19 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT07165015 |
J2S-MC-GZMM | P1 |
Completed |
Kidney Failure, Chronic |
2026-04-16 |
50% |
2026-04-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
jRCT2071250111 |
jRCT2071250111 | P3 |
Not yet recruiting |
Alcoholism |
2028-03-31 |
|||
jRCT2031260413 |
jRCT2031260413 | P2 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-12-05 |
|||
jRCT2071250095 |
jRCT2071250095 | P2 |
Not yet recruiting |
Asthma |
2028-10-16 |
|||
2026-525480-41-00 |
J2S-MC-GZMV | P2 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-09-05 |
79% |
||
2025-522640-41-00 |
J2S-MC-GZMR | P2 |
Not yet recruiting |
Asthma |
2028-06-16 |
|||
jRCT2021250043 |
jRCT2021250043 | P2 |
Not yet recruiting |
Bipolar Disorder |
2028-03-31 |
|||
jRCT2051260167 |
jRCT2051260167 | P3 |
Not yet recruiting |
Depressive Disorder, Major |
2029-01-31 |
|||
NCT07775300 |
RENEW-MDD- 2 | P3 |
Not yet recruiting |
Depressive Disorder, Major |
2028-12-01 |
66% |
2026-08-21 |
|
2025-522310-24-00 |
J2S-MC-GZMI | P3 |
Not yet recruiting |
Depressive Disorder, Major |
2028-05-28 |
66% |
||
NCT07219966 |
RENEW-ALC-1 | P3 |
Recruiting |
Alcoholism |
2028-04-01 |
53% |
2025-12-05 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2025-522313-38-00 |
J2S-MC-GZME | P3 |
Not yet recruiting |
Alcoholism |
2028-04-01 |
53% |
||
2025-522312-16-00 |
J2S-MC-GZMP | P3 |
Not yet recruiting |
Alcoholism |
2028-04-01 |
53% |
Recent News Events
Date |
Type |
Title |
|---|